{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2020.04.09.20059634v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2020.04.09.20059634v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2020.04.09.20059634v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cp id=\u0022p-3\u0022\u003EIn the midst of epidemics such as COVID-19, therapeutic candidates are unlikely to be able to complete the usual multi-year clinical trial and regulatory approval process within the course of an outbreak. We apply a Bayesian adaptive patient-centered model\u2014which minimizes the expected harm of false positives and false negatives\u2014to optimize the clinical trial development path during such outbreaks. When the epidemic is more infectious and fatal, the Bayesian-optimal sample size in the clinical trial is lower and the optimal statistical significance level is higher. For COVID-19 (assuming a static \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 2 and initial infection percentage of 0.1%), the optimal significance level is 7.1% for a clinical trial of a non-vaccine anti-infective therapeutic clinical trial and 13.6% for that of a vaccine. For a dynamic \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E ranging from 2 to 4, the corresponding values are 14.4% and 26.4%, respectively. Our results illustrate the importance of adapting the clinical trial design and the regulatory approval process to the specific parameters and stage of the epidemic.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E1 Introduction\u003C\/h2\u003E\u003Cp id=\u0022p-14\u0022\u003EWith growing public concern over the outbreak of Coronavirus Disease 2019 (COVID-19), significant efforts have been undertaken by global biomedical stakeholders to develop effective diagnostics, vaccines, anti-viral drugs, medical devices, and other therapeutics against this highly infectious and deadly pandemic. While in the past, the traditional randomized clinical trial (RCT) and regulatory approval process often took several years (\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003EU.S. Food \u0026amp; Drug Administration, 2018\u003C\/a\u003E)\u2014longer than the typical duration of an epidemic outbreak (\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003EPronker \u003Cem\u003Eet al\u003C\/em\u003E. 2013\u003C\/a\u003E)\u2014recently the FDA has responded with actions such as the Breakthrough Devices Program, Emergency Use Authorization (EUA) authority, and Immediately in Effect guidance documents to prevent novel diagnostics and therapeutics from lagging behind the urgent needs of the population. In this paper, we propose adapting yet another tool that the FDA has already been exploring for medical devices (\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003EChaudhuri et al. 2018\u003C\/a\u003E, \u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E2019\u003C\/a\u003E) to therapeutics for treating COVID-19 that are currently under development.\u003C\/p\u003E\u003Cp id=\u0022p-15\u0022\u003EIn recent years, Bayesian adaptive RCT protocols have been increasingly used to expedite the clinical trial process of potentially transformative therapies for diseases with high mortality rates (Berry, 2015). Currently, these protocols have mainly been applied within the oncology domain, such as I-SPY for breast cancer (\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003EBarker et al., 2009\u003C\/a\u003E) and GBM AGILE for glioblastoma (Alexander \u003Cem\u003Eet al\u003C\/em\u003E. 2018). These studies use Bayesian inference algorithms to greatly reduce the number of patients needed to assess the therapeutic effects of a drug candidate, without lowering the statistical power of the final approval decision, as measured by Type I and II error rates. As a result, therapeutic candidates can progress more quickly through the regulatory process and reach patients faster and at lower cost.\u003C\/p\u003E\u003Cp id=\u0022p-16\u0022\u003EFor severe diseases with no curative treatments, such as pancreatic cancer, patients tend to tolerate a higher Type I error of accepting an ineffective therapy in exchange for a lower Type II error of rejecting an effective therapy as well as expedited approvals of potentially effective treatments. Based on this observation, a patient-centered Bayesian protocol was proposed (Isakov \u003Cem\u003Eet al\u003C\/em\u003E., 2018; \u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003EMontazerhodjat \u003Cem\u003Eet al\u003C\/em\u003E., 2017\u003C\/a\u003E) that incorporates patient values into clinical trial design and identify the optimal balance between the possibilities of false positives (Type I error) and false negatives (Type II error). For more severe diseases, this protocol sets a tolerated Type I error rate much larger than the traditional 5% threshold, which leads to higher rates of approvals and expedited approval decisions.\u003C\/p\u003E\u003Cp id=\u0022p-17\u0022\u003EHowever, the original Bayesian adaptive RCT framework does not take into account patient risk preferences. To address this gap, \u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo (2018)\u003C\/a\u003E developed an adaptive version of the Bayesian patient-centered model that achieves an optimal balance between Type I and Type II error rates, significantly reducing the number of subjects needed in trials to achieve a statistically significant conclusion. A key feature of this model is the time evolution of the loss function of the Bayesian decision algorithm. This mechanism favors the expedited approval of diagnostic or therapeutic candidates that show early positive effects, since patients place a lower value on delayed approval of an effective diagnostic or therapy.\u003C\/p\u003E\u003Cp id=\u0022p-18\u0022\u003EThere is a natural but subtle analog to this dilemma in the case of therapeutics for an infectious disease during the course of an epidemic outbreak. Approving an effective therapeutic early will prevent future infections and deaths, while approving it later will save fewer people from infection. On the other hand, approving an ineffective therapeutic early will not prevent any future casualties. Worse still, it may prevent people from taking adequate precautions against infection, since they will falsely believe that they are safe from the disease after the advent of the ineffective therapy.\u003C\/p\u003E\u003Cp id=\u0022p-19\u0022\u003EMoreover, the cost of Type I versus Type II error can differ from therapy to therapy. A novel vaccine that could trigger a significant immune response such as a cytokine storm has a much higher cost of a Type I error than a medical device such as an air filtration system designed to destroy virions through intense ultraviolet light. Therefore, the appropriate statistical threshold for approval should depend on the specific therapy, as well as the circumstances of the current burden of disease.\u003C\/p\u003E\u003Cp id=\u0022p-20\u0022\u003EIn this article, we apply the Bayesian adaptive protocol to anti-infective therapeutic development using a loss function that evolves over the course of an epidemic outbreak. We achieve an optimal balance between Type I and Type II errors for therapeutics that treat infectious diseases and identify the optimal time to reach the approval decision based on the accumulation of clinical evidence. Our results show that when the epidemic is more infectious, the necessary sample size of the RCT decreases, while the tolerable Type I error increases. This confirms our earlier intuition that potentially effective therapies that are known to be safe should receive expedited approval when an epidemic is spreading rapidly.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E2 Multi-Group SEIR Epidemic Model\u003C\/h2\u003E\u003Cp id=\u0022p-21\u0022\u003EThe starting point for our analysis is the Susceptible-Exposure-Infective-Removed (SEIR) epidemic model, which has been applied to model the outbreak of COVID-19 in China in a number of recent studies (Yang et al. 2020; \u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003EWu \u003Cem\u003Eet al\u003C\/em\u003E. 2020\u003C\/a\u003E). The population of N subjects is partitioned into four distinct groups: susceptible (S), exposed (E), infectious (I), and removed (R). The time evolution of the epidemic is specified by the following group of ordinary differential equations:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-1.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-1.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cp id=\u0022p-22\u0022\u003EHere we use the convention that \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E), \u003Cem\u003EE\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E), \u003Cem\u003EI\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E), and \u003Cem\u003ER\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) are the proportions of the susceptible, exposed, infectious and removed populations, respectively, satisfying the conservation constraint for all \u003Cem\u003Et\u003C\/em\u003E:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-2\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-2.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-2.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cp id=\u0022p-23\u0022\u003EThe parameters \u003Cem\u003E\u03b2, a\u003C\/em\u003E, and \u003Cem\u003E\u03b3\u003C\/em\u003E denote the average rates of infection, incubation and recovery, respectively, and \u003Cem\u003E\u03bc\u003C\/em\u003E \u2208 (0%, 100%) denotes the mortality rate of the epidemic. For example, if \u003Cem\u003E\u03bc\u003C\/em\u003E = 5%, we expect 5% of infected subjects will die from the disease. At time \u003Cem\u003Et, \u03bcR\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E)\u003Cem\u003EN\u003C\/em\u003E subjects will have died, and (1 - \u003Cem\u003E\u03bc\u003C\/em\u003E)\u003Cem\u003ER\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E)\u003Cem\u003EN\u003C\/em\u003E will have recovered.\u003C\/p\u003E\u003Cp id=\u0022p-24\u0022\u003EA critical measure of the infectivity of an epidemic is its basic reproduction number, defined as \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = \u003Cem\u003E\u03b2\u003C\/em\u003E\/\u003Cem\u003E\u03b3\u003C\/em\u003E in the SEIR model. This is the expected number of secondary infections caused by each infected subject in a population with no public health measures (such as quarantine, social-distancing, or vaccination).\u003C\/p\u003E\u003Cp id=\u0022p-25\u0022\u003EA number of studies have used different statistical schemes to estimate \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E for COVID-19 during its initial outbreak period in central China in January 2020. These estimated values of \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E range from 2.2 (95% CI, 1.4 to 3.9) (Li \u003Cem\u003Eet al\u003C\/em\u003E., 2020) to 3.58 (95% CI, 2.89 to 4.39) (Zhao \u003Cem\u003Eet al\u003C\/em\u003E., 2020). Given the large uncertainty in the value of \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, we simulate therapeutic development under scenarios with constant \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E values of 2 and 4.\u003C\/p\u003E\u003Cp id=\u0022p-26\u0022\u003EIn addition, to model the impact of governmental nonpharmaceutical interventions (NPIs) on containing the spread of the epidemic, we consider a dynamic transmission SEIR model where the infection rate \u003Cem\u003E\u03b2\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) monotonically decreases in time as a result of the NPI. Specifically, we assume that \u003Cem\u003E\u03b2\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) takes the sigmoid functional form:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-3\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-3.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-3.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cp id=\u0022p-27\u0022\u003EHere \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E and \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E denote the infection rates in the initial and final stages of the epidemic (with \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E \u0026gt; \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E), respectively, \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E denotes the half-life of the decay in infection rate, and \u003Cem\u003E\u03c4\u003C\/em\u003E the length of the time window when this decay occurred. A larger difference \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E - \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E corresponds to more significant reduction of epidemic transmission, a smaller value of \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E corresponds to a speedier decision to enforce the NPI, and a smaller value of \u003Cem\u003E\u03c4\u003C\/em\u003E corresponds to more strict enforcement of the NPI since \u003Cem\u003E\u03b2\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) decays more rapidly. We calibrate the values \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 3 and \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E = 1.5 based on the estimates of the dynamic transmission rate of COVID-19 in Wuhan, China from December 2019 to February 2020 (Kucharski \u003Cem\u003Eet al\u003C\/em\u003E., 2020). We consider different values of \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E and \u003Cem\u003E\u03c4\u003C\/em\u003E to reflect the variability in timing and stringency of NPIs enforced by governments around the globe.\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003ETo model the significant variability in mortality rates of COVID-19 for patients in different age groups, we extend this basic model to a multi-group SEIR model, where the population is partitioned into five age groups, (1) below 49, (2) 50 to 59, (3) 60 to 69, (4) 70 to 79, and (5) above 80. We use \u003Cem\u003ES\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E, \u003Cem\u003EE\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E, \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E, and \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E to denote the corresponding type in each group (and continue to use \u003Cem\u003ES, E, I\u003C\/em\u003E, and \u003Cem\u003ER\u003C\/em\u003E for the total proportion of each type in all groups). The dynamics of the epidemic are specified by the modified ordinary differential equations:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-4\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-4.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-4.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EHere \u003Cem\u003Ec\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E denotes the contact rate of the susceptible subjects in the \u003Cem\u003Ei\u003C\/em\u003E\u003Csup\u003Eth\u003C\/sup\u003E age group with the total infected population \u003Cem\u003EI\u003C\/em\u003E of all groups. This contact rate is measured relative to group 1, which we normalize to \u003Cem\u003Ec\u003C\/em\u003E\u003Csub\u003El\u003C\/sub\u003E = 1. In the case of COVID-19, although the mortality rate is much higher for senior populations (\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003EOnder \u003Cem\u003Eet al\u003C\/em\u003E., 2020\u003C\/a\u003E), the elderly also tends to have less frequent contact with the infected population outside the household (\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003EWalker \u003Cem\u003Eet al\u003C\/em\u003E., 2020\u003C\/a\u003E).\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EWe solve the differential equations in the multi-group SEIR model using the ODE45 solver in MATLAB 2019a with initial conditions for each age group:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-5\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-5.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-5.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EThe parameter \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the proportion of the initially infected population, \u003Cem\u003Er\u003C\/em\u003E\u003Csub\u003Ee\u003C\/sub\u003E is the ratio of initially exposed and infected subjects, and \u003Cem\u003EP\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E is the percentage of the \u003Cem\u003Ei\u003C\/em\u003E\u003Csup\u003Eth\u003C\/sup\u003E age group in the population. The assumed demographic, contact rate, and mortality rate values are summarized in \u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-3\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E3 A Bayesian Patient-Centered Approval Process\u003C\/h2\u003E\u003Cp id=\u0022p-32\u0022\u003ESimilar to \u003Ca id=\u0022xref-ref-3-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo (2018)\u003C\/a\u003E, we develop a Bayesian patient-centered decision model for RCT approval which minimizes the expected loss (or harm) incurred on the patients by optimally balancing the losses of Type I and Type II errors. Here the loss does not refer to financial costs afforded by the patients, but rather the loss in patient value (i.e. how much patients weigh the relative harms of infection and death). We assign the losses per patient of being susceptible, infected, and deceased. Since Bayesian decision thresholds are invariant under the rescaling of the losses, we normalize by setting the loss per patient infection \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E = 1. We then assign the loss per patient death relative to \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003Ei\u003C\/em\u003E\u003C\/sub\u003E as \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003ED\u003C\/sub\u003E, and the loss due to susceptibility to the disease as \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003ES\u003C\/sub\u003E. The parameter values we assume, summarized in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E, are meant to represent one reasonable valuation of the relative losses. However, in practice patient value will differ from one patient group another, especially given the large variability of mortality rate of COVID-19 in different age groups (\u003Ca id=\u0022xref-ref-13-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003EOnder \u003Cem\u003Eet al\u003C\/em\u003E., 2020\u003C\/a\u003E). Here we report the main results of optimal sample size and statistical significance (\u003Ca id=\u0022xref-table-wrap-3-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E and \u003Ca id=\u0022xref-table-wrap-4-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003E4\u003C\/a\u003E) assuming \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003ED\u003C\/sub\u003E = 100. The results for \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003ED\u003C\/sub\u003E = 10 are provided in Supplementary Materials.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157531\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157531\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157531\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003ESimulation parameters and values.\u003C\/span\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157527\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157527\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157527\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \u003Cp id=\u0022p-33\u0022 class=\u0022first-child\u0022\u003EDemographic (US Census Bureau, 2018), relative contact rate (\u003Ca id=\u0022xref-ref-18-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003EWalker \u003Cem\u003Eet al\u003C\/em\u003E. 2020\u003C\/a\u003E) and mortality (\u003Ca id=\u0022xref-ref-13-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003EOnder \u003Cem\u003Eet al\u003C\/em\u003E. 2020\u003C\/a\u003E; \u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003EWorld Health Organization 2003\u003C\/a\u003E; 2019; 2020) profile of various age groups for COVID-19, SARS and MERS.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T3\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157512\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157512\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157512\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 3.\u003C\/span\u003E \u003Cp id=\u0022p-34\u0022 class=\u0022first-child\u0022\u003ESimulation results of a Bayesian adaptive RCT on non-vaccine anti-infective therapeutics obtained from 10,000 Monte Carlo runs and assuming \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E-\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 100. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the basic reproduction number, \u003Cem\u003E\u00b5\u003C\/em\u003E the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size refers to the number of subjects enrolled in each arm of the RCT. SD denotes standard deviation, and IQR the interquartile range about the median. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E(t) denotes the use of a dynamic transmission model with half-life \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks and window length \u03c4 = 1 week.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T4\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157502\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157502\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157502\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 4.\u003C\/span\u003E \u003Cp id=\u0022p-35\u0022 class=\u0022first-child\u0022\u003ESimulation results of Bayesian adaptive RCT for vaccines obtained from 10,000 Monte Carlo runs and assuming \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 100. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the basic reproduction number, \u003Cem\u003E\u00b5\u003C\/em\u003E the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size refers to the number of subjects enrolled in each arm of the RCT. SD denotes standard deviation, and IQR the interquartile range about the median. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E(t) denotes the use of a dynamic transmission model with half-life \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks and window length \u03c4 = 1 week.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-36\u0022\u003EWe simulate the multi-group SEIR model over a time period of \u003Cem\u003ET\u003C\/em\u003E weeks, where \u003Cem\u003ET\u003C\/em\u003E is the duration of the epidemic outbreak. Let \u003Cem\u003E\u03ba\u003C\/em\u003E denote the weekly subject enrollment rate in each arm of the clinical trial. We assume that the value of \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E is known (or well-estimated) at initial time \u003Cem\u003Et\u003C\/em\u003E = 0 and stays constant during the course of the outbreak. At time \u003Cem\u003Et\u003C\/em\u003E \u2208 [0, \u003Cem\u003ET\u003C\/em\u003E], the Bayesian loss C\u003Csub\u003Eij\u003C\/sub\u003E(t) of choosing the action \u003Cem\u003E\u0124\u003C\/em\u003E = \u003Cem\u003Ei\u003C\/em\u003E under \u003Cem\u003EH\u003C\/em\u003E = \u003Cem\u003Ej\u003C\/em\u003E is defined as:\n\nwhere we define the cumulative number of infected patients \u003Cem\u003ECI\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) until time t:\n\u003Cspan class=\u0022disp-formula\u0022 id=\u0022disp-formula-6\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-11.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/graphic-11.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\n\n\u003C\/span\u003E\u003C\/p\u003E\u003Cdiv id=\u0022T5\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157501\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157501\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157501\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-37\u0022\u003EBy design, this loss function penalizes Type I errors early in the epidemic by the susceptible term, (\u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) - \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E))\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003ES\u003C\/sub\u003E. We subtract the base level \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E) from \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) since the multi-group SEIR model predicts that \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E)\u003Cem\u003EN\u003C\/em\u003E subjects will not be infected by the epidemic. A Type I error at an earlier time will expose more currently susceptible population to the epidemic, since they will falsely believe that they are safe from the disease after the advent of the ineffective therapeutic. On the other hand, the loss function also penalizes \u003Cem\u003Ecorrect\u003C\/em\u003E approval decisions made at later stages of an epidemic via to the cumulative infected and death terms, \u003Cem\u003ECI\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) and \u003Cem\u003E\u03bcR\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E). A correct but delayed approval decision for the therapeutic is less valuable since it will save fewer susceptible people from infection and death.\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EThe Bayesian decision model considers the null hypothesis \u003Cem\u003EH\u003C\/em\u003E = 0 that the anti-infective therapeutic (or vaccine) has no clinical effect, against the alternative hypothesis that it has positive clinical effect with signal-to-noise ratio \u003Cem\u003E\u03c1\u003C\/em\u003E (\u003Ca id=\u0022xref-ref-3-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo, 2018\u003C\/a\u003E). We use \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003Eand \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003El\u003C\/sub\u003E to denote the Bayesian prior probabilities of \u003Cem\u003EH\u003C\/em\u003E = 0 and \u003Cem\u003EH\u003C\/em\u003E = 1, respectively.\u003C\/p\u003E\u003Cp id=\u0022p-39\u0022\u003EThis patient-value model imposes higher losses for incorrect approvals at earlier stages and correct approvals at later stages of an epidemic. Under these constraints, the Bayesian decision algorithm yields the sample size and statistical significance threshold of the RCT that optimally balances Type I and Type II error.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-4\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4 Results\u003C\/h2\u003E\u003Cp id=\u0022p-40\u0022\u003EWe simulate an epidemic outbreak over a time period of \u003Cem\u003ET\u003C\/em\u003E weeks, where \u003Cem\u003ET\u003C\/em\u003E is the duration of the outbreak. For an epidemic with higher infectivity, its duration is shorter, which puts more pressure to reach a timely approval decision. To avoid numerical instability, we formally define \u003Cem\u003ET\u003C\/em\u003E as the first time when the number of cumulative infected patients reaches 99.9% of total infections predicted by the SEIR model. We assume an age-specific mortality rate \u003Cem\u003E\u03bc\u003C\/em\u003E at the level of COVID-19 (\u003Ca id=\u0022xref-ref-13-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003EOnder \u003Cem\u003Eet al\u003C\/em\u003E. 2020\u003C\/a\u003E; \u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003EWorld Health Organization, 2020\u003C\/a\u003E), and incubation and recovery periods of 7 days each (Yang \u003Cem\u003Eet al\u003C\/em\u003E. 2020). These estimated parameters can all be challenged to varying degrees, depending on the specific drug-indication pair under consideration and the particular circumstances of the epidemic, but they are meant to be representative for a typical anti-infective therapeutic during the midst of a growing epidemic.\u003C\/p\u003E\u003Cp id=\u0022p-41\u0022\u003EWe also assume that it takes 7 days after injection to assess the efficacy of the therapeutic on each subject. We adopt the optimization scheme of \u003Ca id=\u0022xref-ref-9-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003EMontazerhodjat \u003Cem\u003Eet al\u003C\/em\u003E. (2017)\u003C\/a\u003E to find the optimal Type I and Type II error rates of the non-adaptive Bayesian RCT. To represent typical practice of the pharmaceutical industry, we optimize under the upper bound on the model\u2019s power Power\u003Csub\u003Emax\u003C\/sub\u003E = 90% (\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003EIsakov \u003Cem\u003Eet al\u003C\/em\u003E. 2019\u003C\/a\u003E). We then use these optimal error rates as our stopping criteria to simulate the sequential decision process of a Bayesian adaptive RCT via Monte Carlo simulation (\u003Ca id=\u0022xref-ref-3-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo, 2018\u003C\/a\u003E). The simulation results are summarized in \u003Ca id=\u0022xref-table-wrap-3-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-42\u0022\u003EWe separate the results into two distinct types of therapeutics\u2014non-vaccine anti-infectives and vaccines\u2014because of the differences in their historical probabilities of success. Vaccine development programs have an estimated PoS of 40% as of 2019Q4 (\u003Ca href=\u0022https:\/\/projectalpha.mit.edu\u0022\u003Ehttps:\/\/projectalpha.mit.edu\u003C\/a\u003E) whereas the corresponding figure for non-vaccine anti-infectives is 23% (\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003EWong et al., 2020\u003C\/a\u003E).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-5\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4.1 Non-Vaccine Anti-Infective Therapeutics\u003C\/h2\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatic Transmission Rate\u003C\/h3\u003E\u003Cp id=\u0022p-43\u0022\u003EWe first analyze the case when the infectivity \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E remains constant in time (e.g. in the absence of effective NPIs). For the fixed-sample Bayesian RCT on a non-vaccine anti-infective therapeutic, as \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E increases from 2 to 4 (Rows 1 to 2 of \u003Ca id=\u0022xref-table-wrap-3-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E), the optimal sample size of each experimental arm decreases from 242 to 152 and the optimal Type I error rate drastically increases from 7.1% to 17.3% (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E), much higher than the traditional 5% threshold. As the epidemic spreads across the population more rapidly, the Bayesian RCT model has greater pressure to expedite the approval process and a much higher tolerance of false positive outcomes.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Optimal Type I error rate \u0026#x3B1; of a non-adaptive Bayesian RCT vs. basic reproduction number R0 (assuming I0 = 0. 1%, LD = 100, disease mortality of COVID- 19, and constant R0). The Bayesian decision model yields a higher \u0026#x3B1; for epidemics with high and low infectivity.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Optimal Type I error rate \u0026lt;em\u0026gt;\u0026#x3B1;\u0026lt;\/em\u0026gt; of a non-adaptive Bayesian RCT vs. basic reproduction number \u0026lt;em\u0026gt;R\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; (assuming \u0026lt;em\u0026gt;I\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; = 0. 1%, \u0026lt;em\u0026gt;L\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;D\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; = 100, disease mortality of COVID- 19, and constant \u0026lt;em\u0026gt;R\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt;). The Bayesian decision model yields a higher \u0026lt;em\u0026gt;\u0026#x3B1;\u0026lt;\/em\u0026gt; for epidemics with high and low infectivity.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022366\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022366\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-44\u0022 class=\u0022first-child\u0022\u003EOptimal Type I error rate \u003Cem\u003E\u03b1\u003C\/em\u003E of a non-adaptive Bayesian RCT vs. basic reproduction number \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (assuming \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 0. 1%, \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 100, disease mortality of COVID- 19, and constant \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E). The Bayesian decision model yields a higher \u003Cem\u003E\u03b1\u003C\/em\u003E for epidemics with high and low infectivity.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-45\u0022\u003EFor the Bayesian adaptive RCT, when the therapeutic is ineffective (\u003Cem\u003EH\u003C\/em\u003E = 0), the average sample size required to reject the therapeutic is much smaller than that of the non-adaptive version (Columns 7 and 8 of \u003Ca id=\u0022xref-table-wrap-3-4\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E). Also, the required sample size decreases with the infectivity \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E in both mean and quartiles, yet always achieves Type I error rate \u003Cem\u003E\u03b1\u003C\/em\u003E below that of the non-adaptive version (Column 11). The adaptive Bayesian decision model is able to reject an ineffective therapeutic with a relatively small sample size and a bounded false-positive rate.\u003C\/p\u003E\u003Cp id=\u0022p-46\u0022\u003EOn the other hand, when the therapeutic is effective (\u003Cem\u003EH\u003C\/em\u003E = 1), as \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E increases from 2 to 4, the average sample size required by the Bayesian adaptive RCT decreases from 148 to 78 (Columns 9 and 10 of \u003Ca id=\u0022xref-table-wrap-3-5\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E). The Bayesian adaptive model places more weight on approving an effective therapeutic earlier to prevent future infections when the epidemic is more infectious. Despite the smaller sample size, the model still retains an empirical power above 91.0% for all values of \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (Column 12). The Bayesian adaptive model simultaneously expedites the approval of an effective therapeutic and retains a bounded false-negative rate. The results are illustrated in \u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Subject sample size in each arm of a Bayesian adaptive RCT under H = 1 decreases with the basic reproduction number R0 (assuming I0 = 0. 1%, LD = 100 and disease mortality of COVID-19). BNA denotes Bayesian non-adaptive optimal; BA 50% denotes median patient size of Bayesian adaptive. The 25% and 75% quantiles of Bayesian adaptive patient size are shown as lower and upper ends of the error bar.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Subject sample size in each arm of a Bayesian adaptive RCT under H = 1 decreases with the basic reproduction number \u0026lt;em\u0026gt;R\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; (assuming \u0026lt;em\u0026gt;I\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; = 0. 1%, \u0026lt;em\u0026gt;L\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;D\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; = 100 and disease mortality of COVID-19). BNA denotes Bayesian non-adaptive optimal; BA 50% denotes median patient size of Bayesian adaptive. The 25% and 75% quantiles of Bayesian adaptive patient size are shown as lower and upper ends of the error bar.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022364\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022364\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \u003Cp id=\u0022p-47\u0022 class=\u0022first-child\u0022\u003ESubject sample size in each arm of a Bayesian adaptive RCT under H = 1 decreases with the basic reproduction number \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (assuming \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 0. 1%, \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 100 and disease mortality of COVID-19). BNA denotes Bayesian non-adaptive optimal; BA 50% denotes median patient size of Bayesian adaptive. The 25% and 75% quantiles of Bayesian adaptive patient size are shown as lower and upper ends of the error bar.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-48\u0022\u003EFurthermore, as the proportion of the initially infected population \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E decreases from 0.1% to 0.01% (Rows 4 to 6 of \u003Ca id=\u0022xref-table-wrap-3-6\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E), the optimal sample sizes for non-adaptive and adaptive RCTs both increase, while the optimal Type I error rates decrease. Beginning the clinical trials for a therapeutic during the earlier stages of an epidemic outbreak reduces the need to expedite the approval process in order to contain its future spread. Clinicians and researchers have more time to evaluate the efficacy of a therapeutic and record adverse effects by testing it on a larger number of subjects, which leads to a lower Type I error rate.\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003EFinally, when the mortality rate \u003Cem\u003E\u03bc\u003C\/em\u003E increases from the level of COVID-19 (\u003Ca id=\u0022xref-ref-13-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003EOnder \u003Cem\u003Eet al\u003C\/em\u003E. 2020\u003C\/a\u003E; \u003Ca id=\u0022xref-ref-21-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003EWorld Health Organization, 2020\u003C\/a\u003E), to the level of SARS (\u003Ca id=\u0022xref-ref-22-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003EWorld Health Organization, 2003\u003C\/a\u003E), and further to the level MERS (\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003EWorld Health Organization, 2019\u003C\/a\u003E), the optimal sample sizes for both non-adaptive and adaptive Bayesian models decrease and the optimal Type I error rates increase (Rows 7 to 12 of \u003Ca id=\u0022xref-table-wrap-3-7\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E). When the epidemic is more lethal, the Bayesian adaptive model requires fewer subjects in the RCT, since both Type I and Type II errors will lead to greater losses due to death by infection. The higher death tolls provides significantly more incentive in the Bayesian adaptive framework to approve the therapeutic in the hopes of saving more people from future infection and death.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EOne interesting feature of the Bayesian decision model is that the optimal Type I error rate is not a monotonic function \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, but rather has a global minimum of 8% at \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 1.7 for COVID-19, as shown in \u003Ca id=\u0022xref-fig-1-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E. As \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E decreases below 1.7, the optimal Type I error rate increases. The intuition for this result that we define the loss of Type I error as the excess risk of being susceptible to infection (\u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) - \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E))\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003ES\u003C\/sub\u003E, where \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E) is the fraction of the population that remains uninfected throughout the epidemic outbreak. When \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E is small, \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E) is close to 100% and the excess risk (\u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) - \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E))\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003ES\u003C\/sub\u003E is small compared to the benefit of preventing future deaths. Therefore, when the epidemic is not very infectious, the Bayesian decision model expedites the approval decision. This also confirms the intuition that smaller sample sizes are required in adaptive trials for diseases that affect a small fraction of the population. If we instead define the loss of Type I error as the absolute risk of being susceptible \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E)\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003ES\u003C\/sub\u003E, we find that the optimal Type I error indeed monotonically increases with \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, as shown in \u003Ca id=\u0022xref-fig-11-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F11\u0022\u003EFigure 11\u003C\/a\u003E of Supplementary Materials.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDynamic Transmission Rate\u003C\/h3\u003E\u003Cp id=\u0022p-51\u0022\u003EThe results for the dynamic transmission model with \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 3, \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E = 1.5, \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks and \u003Cem\u003E\u03c4\u003C\/em\u003E = 1 week are summarized in \u003Ca id=\u0022xref-table-wrap-3-8\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E. For COVID-19 (rows 3 and 6), we find that the Bayesian optimal sample size and Type I error rate of the dynamic transmission model lie in between the scenarios \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 2 and \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 4. This suggests that timely and effective government interventions will protect more subjects from infection and allow more time for the RCT.\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003EHowever, for the more fatal SARS and MERS (rows 9 and 12), the dynamic transmission model sets higher optimal Type I error \u003Cem\u003E\u03b1\u003C\/em\u003E and smaller sample size than \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 4. This is due to the U-shaped curve of optimal \u003Cem\u003E\u03b1\u003C\/em\u003E vs. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E, shown in \u003Ca id=\u0022xref-fig-1-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E. When the NPI reduces \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E(\u003Cem\u003Et\u003C\/em\u003E) below a certain threshold, the optimal \u003Cem\u003E\u03b1\u003C\/em\u003E starts to increase. For highly fatal epidemics, when the government adopts NPIs to protect most of the susceptible population from infection, the regulatory priority should be to expedite potentially effective treatments that can help current patients since the loss of Type I error is much lower than that of the Type II error.\u003C\/p\u003E\u003Cp id=\u0022p-53\u0022\u003EIn addition, we investigate the impact of the timing and stringency of NPIs enforced by the government with different values of \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E and \u003Cem\u003E\u03c4\u003C\/em\u003E. The results are summarized in \u003Ca id=\u0022xref-table-wrap-6-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T6\u0022\u003ETable 5\u003C\/a\u003E. We find that the optimal Type I error is larger for \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks than \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 6 weeks. Therefore, if the government adopts well-enforced NPIs early on (such as the lockdown of Wuhan, China) to protect the susceptible population, this will reduce the loss associated with Type I error, leading to expedited approvals of potentially effective therapeutics. Furthermore, the sooner an effective therapeutic is approved, the sooner will NPIs be lifted.\u003C\/p\u003E\u003Cdiv id=\u0022T6\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157517\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157517\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157517\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 5.\u003C\/span\u003E \u003Cp id=\u0022p-54\u0022 class=\u0022first-child\u0022\u003EOptimal sample size and Type I error \u003Cem\u003E\u03b1\u003C\/em\u003E of Bayesian non-adaptive RCT for non-vaccine anti-infective therapeutics for dynamic transmission model. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the basic reproduction number, \u003Cem\u003E\u00b5\u003C\/em\u003E the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size refers to the number of subjects enrolled in each arm of the RCT. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E(t) denotes the use of a dynamic transmission model with \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 3, \u003Cem\u003E\u03b2\u003C\/em\u003E\u003Csub\u003E\u221e\u003C\/sub\u003E = 1. 5.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E4.2 Vaccines\u003C\/h3\u003E\u003Cp id=\u0022p-55\u0022\u003EWe repeat the above analysis for RCT of vaccines using a prior probability of having an effective vaccine \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E as reported at \u003Ca href=\u0022https:\/\/projectalpha.mit.edu\u0022\u003Ehttps:\/\/projectalpha.mit.edu\u003C\/a\u003E for 2019Q4. The simulation results are summarized in \u003Ca id=\u0022xref-table-wrap-4-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T4\u0022\u003ETable 4\u003C\/a\u003E. Overall, we observe the same pattern in the optimal sample size and Type I error rates on infectivity, mortality, and proportion of initial infections. However, since \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003El\u003C\/sub\u003E is higher for vaccines, the Bayesian decision model requires fewer subjects on average in the RCT to ascertain the positive effects of the vaccine, compared to the case of anti-infective therapeutics in \u003Ca id=\u0022xref-table-wrap-3-9\u0022 class=\u0022xref-table\u0022 href=\u0022#T3\u0022\u003ETable 3\u003C\/a\u003E. We find that vaccines should receive even more expedited evaluation.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003ETo assess the robustness of our model\u2019s predictions against the assumed values of model parameters, we perform a sensitivity analysis on the parameter values. The results are summarized in Supplementary Materials.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-9\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E5 Discussion\u003C\/h2\u003E\u003Cp id=\u0022p-57\u0022\u003EA natural consequence of using a patient-centered framework for determining the approval threshold is, of course, more false positives\u2014and the potential for a greater number of patients with adverse side-effects\u2014in cases where the burden of disease is high. These false positives can be addressed through more vigilant post-approval surveillance by regulatory agencies and greater requirements for drug and device companies to provide such patient-level data to the regulator following approval. Failure to provide such data or evidence of an ineffective therapy can be grounds for revoking the approval.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003EHowever, past experience shows that withdrawing an approved drug can be challenging and disruptive for several reasons (\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003EOnakpoya, Heneghan, and Aronson, 2016\u003C\/a\u003E). Therefore, implementing the patient-centered approach may require creating a new category of temporary approvals for crisis situations involving urgent needs at national or international levels, similar to the FDA\u2019s EUA program. Such a program might involve provisional approval of a candidate therapy consisting of a one- or two-year license\u2014depending on the nature of the drug-indication pair\u2014to market the therapy to a pre-specified patient population, no off-label use of the therapy, and regular monitoring and data reporting to the regulator by the manufacturer and\/or patients\u2019 physicians during the licensing period (\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003ELo, 2017\u003C\/a\u003E). At the end of this trial period, one of two outcomes would occur, depending on the accumulated data during this period: (a) the \u201curgent needs\u201d license expires; or (b) the license converts to the traditional regulatory license. Of course, at any point during the trial period, the regulator can terminate the license if the data show that the therapeutic is ineffective and\/or unsafe.\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EWhile such a process may impose greater burdens on patients, manufacturers, and regulators, it may still be worthwhile if it brings faster or greater relief to patients facing mortal illnesses and extreme suffering. In this respect, an urgent-needs program may be viewed as a middle ground between a standard clinical trial and an approval, similar in spirit to the adaptive designs of sophisticated clinical trials with master protocols such as I-SPY 2, LUNG-MAP, and GBM-AGILE, in which patient care and clinical investigations are simultaneously accomplished. Also, because the Centers for Medicare and Medicaid Services (CMS) has demonstrated a willingness to cover the cost of certain therapeutics for which evidence is still being generated (see, for example, CMS\u2019s \u201ccoverage with evidence\u201d programs listed at \u003Ca href=\u0022https:\/\/go.cms.gov\/2v6ZxWm\u0022\u003Ehttps:\/\/go.cms.gov\/2v6ZxWm\u003C\/a\u003E), additional economic incentives may be available to support such temporary licenses.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-10\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E6 Conclusion\u003C\/h2\u003E\u003Cp id=\u0022p-60\u0022\u003EWe apply the Bayesian adaptive patient-centered model of \u003Ca id=\u0022xref-ref-3-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo (2018)\u003C\/a\u003E to clinical trials for therapeutics that treat infectious diseases during an epidemic outbreak. Using a simple epidemiological model, we find that the optimal sample size in the clinical trial decreases with the infectivity of the epidemic, measured by the basic reproduction number \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E. At the same time, the optimal Type I error rate increases with \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E. Lower levels of initial infection increase the number of subjects required to verify the therapeutic efficacy of the therapeutic under investigation, while higher levels of mortality increase the optimal sample size. The results confirm our intuition that clinical trials should be expedited and a higher false positive rate should be tolerated when the epidemic spreads more rapidly through the population, has a higher mortality rate, and has already infected a sizable portion of the population at the beginning of the RCT.\u003C\/p\u003E\u003Cp id=\u0022p-61\u0022\u003ETo provide transparency for how a patient-centered approach differs from the traditional statistical framework in the anti-infectives context, we used a relatively simple mathematical model of epidemic disease dynamics to estimate the societal loss in an outbreak. More sophisticated epidemiological models can easily be incorporated into our framework at the cost of computational tractability and transparency.\u003C\/p\u003E\u003Cp id=\u0022p-62\u0022\u003EOne interesting trade-off to be explored is the difference between COVID-19 vaccine and an anti-viral treatment that can cure an infected patient. While prevention through vaccination is the ultimate solution, a successful treatment for the disease using repurposed drugs that have already been approved for other indications (and whose safety profile has already been established) may be even more valuable, especially if it can be deployed in the nearer term and reduce the growing fear and panic among the general population. In such cases, the approval threshold should clearly reflect these cost\/benefit differences.\u003C\/p\u003E\u003Cp id=\u0022p-63\u0022\u003EOf course, in practice regulators consider many factors beyond \u003Cem\u003Ep\u003C\/em\u003E-values in making its decisions. However, that process is opaque even to industry insiders, and the role of patient preferences is unclear. The proposed patient-centered approach provides a systematic, objective, adaptive, and repeatable framework for explicitly incorporating patient preferences and burden-of-disease data in the therapeutic approval process. This framework also fulfills two mandates for the FDA, one from the fifth authorization of the Prescription Drug User Fee Act (PDUFA) for an enhanced quantitative approach to the benefit-risk assessment of new drugs (U.S FDA, 2013), and the other from Section 3002 of the 21\u003Csup\u003Est\u003C\/sup\u003E Century Cures Act of 2016 requiring the FDA to develop guidelines for patient-focused drug development, which includes collecting patient preference and experience data and explicitly incorporating this information in the drug approval process.\u003C\/p\u003E\u003Cp id=\u0022p-64\u0022\u003EWe hope this work will shed further insight into improving the current clinical trial process for infectious disease therapeutics and contribute to the timely development of effective treatments for COVID-19 patients in particular.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-11\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-65\u0022\u003EAll data used in this project are commercially available to other authors on the same terms.\u003C\/p\u003E\u003Cp id=\u0022p-66\u0022\u003E\n\u003Ca href=\u0022https:\/\/informa.com\u0022\u003Ehttps:\/\/informa.com\u003C\/a\u003E\n\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-12\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ESupplementary Materials\u003C\/h2\u003E\u003Cdiv id=\u0022F3\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F3.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the weekly subject enrollment rate \u0026#x3BA;. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3BA; = 100 used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the weekly subject enrollment rate \u0026lt;em\u0026gt;\u0026#x3BA;\u0026lt;\/em\u0026gt;. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026lt;em\u0026gt;\u0026#x3BA;\u0026lt;\/em\u0026gt; = 100 used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 3.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022421\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 3.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022421\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F3.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 3.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F3.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 3.\u003C\/span\u003E \u003Cp id=\u0022p-67\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the weekly subject enrollment rate \u003Cem\u003E\u03ba\u003C\/em\u003E. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u003Cem\u003E\u03ba\u003C\/em\u003E = 100 used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-2\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F4\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F4.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal Type I error rate to the weekly subject enrollment rate \u0026#x3BA;. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3BA; = 100 used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal Type I error rate to the weekly subject enrollment rate \u0026lt;em\u0026gt;\u0026#x3BA;\u0026lt;\/em\u0026gt;. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026lt;em\u0026gt;\u0026#x3BA;\u0026lt;\/em\u0026gt; = 100 used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 4.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022419\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 4.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F4.medium.gif\u0022 width=\u0022440\u0022 height=\u0022419\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F4.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 4.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F4.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 4.\u003C\/span\u003E \u003Cp id=\u0022p-68\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal Type I error rate to the weekly subject enrollment rate \u003Cem\u003E\u03ba\u003C\/em\u003E. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u003Cem\u003E\u03ba\u003C\/em\u003E = 100 used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-3\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F5\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F5.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the signal to noise ratio (SNR) \u0026#x3C1; of treatment effect (Chaudhuri and Lo, 2018). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3C1; = 0. 25 used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the signal to noise ratio (SNR) \u0026#x3C1; of treatment effect (Chaudhuri and Lo, 2018). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3C1; = 0. 25 used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 5.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022426\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 5.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022426\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F5.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 5.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F5.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 5.\u003C\/span\u003E \u003Cp id=\u0022p-69\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the signal to noise ratio (SNR) \u03c1 of treatment effect (\u003Ca id=\u0022xref-ref-3-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo, 2018\u003C\/a\u003E). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u03c1 = 0. 25 used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-4\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F6\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F6.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal Type I error rate to the signal to noise ratio (SNR) \u0026#x3C1; of treatment effect (Chaudhuri and Lo, 2018). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3C1; = 0. 25 used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Sensitivity of optimal Type I error rate to the signal to noise ratio (SNR) \u0026#x3C1; of treatment effect (Chaudhuri and Lo, 2018). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026#x3C1; = 0. 25 used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 6.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F6.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 6.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F6.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F6.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 6.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F6.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 6.\u003C\/span\u003E \u003Cp id=\u0022p-70\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal Type I error rate to the signal to noise ratio (SNR) \u03c1 of treatment effect (\u003Ca id=\u0022xref-ref-3-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003EChaudhuri and Lo, 2018\u003C\/a\u003E). From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u03c1 = 0. 25 used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-5\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F7\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F7.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the prior probability of having an ineffective treatment p0. From the lower to upper end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value p0 = 77% used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the prior probability of having an ineffective treatment \u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt;. From the lower to upper end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value \u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; = 77% used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 7.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F7.medium.gif\u0022 width=\u0022440\u0022 height=\u0022424\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 7.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F7.medium.gif\u0022 width=\u0022440\u0022 height=\u0022424\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F7.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 7.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F7.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 7.\u003C\/span\u003E \u003Cp id=\u0022p-71\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the prior probability of having an ineffective treatment \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E. From the lower to upper end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 77% used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-6\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F8\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F8.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal Type I error rate to the prior probability of having an ineffective treatment p0. From the upper to lower end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value p0 = 77% used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal Type I error rate to the prior probability of having an ineffective treatment \u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt;. From the upper to lower end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value \u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; = 77% used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 8.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F8.medium.gif\u0022 width=\u0022440\u0022 height=\u0022422\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 8.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F8.medium.gif\u0022 width=\u0022440\u0022 height=\u0022422\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F8.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 8.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F8.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 8.\u003C\/span\u003E \u003Cp id=\u0022p-72\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal Type I error rate to the prior probability of having an ineffective treatment \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E. From the upper to lower end of each box plot, the five-parameter summary corresponds to [70%, 85%, 100%, 115%, 125%] of the baseline value \u003Cem\u003Ep\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 77% used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-7\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F9\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F9.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the time to assess the efficacy of the non-vaccine anti-infective therapeutics \u0026#x394;t. From the upper to lower end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0026#x394;t = 1 week used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the time to assess the efficacy of the non-vaccine anti-infective therapeutics \u0026#x394;\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt;. From the upper to lower end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0026#x394;\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt; = 1 week used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 9.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F9.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 9.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F9.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F9.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 9.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F9.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 9.\u003C\/span\u003E \u003Cp id=\u0022p-73\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the time to assess the efficacy of the non-vaccine anti-infective therapeutics \u0394\u003Cem\u003Et\u003C\/em\u003E. From the upper to lower end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0394\u003Cem\u003Et\u003C\/em\u003E = 1 week used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-8\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F10\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F10.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal Type I error rate to the time to assess the efficacy of the anti-infective therapeutic \u0026#x394;t. From the lower to upper end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0026#x394;t = 1 week used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal Type I error rate to the time to assess the efficacy of the anti-infective therapeutic \u0026#x394;\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt;. From the lower to upper end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0026#x394;\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt; = 1 week used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 10.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F10.medium.gif\u0022 width=\u0022440\u0022 height=\u0022421\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 10.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F10.medium.gif\u0022 width=\u0022440\u0022 height=\u0022421\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F10.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 10.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F10.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 10.\u003C\/span\u003E \u003Cp id=\u0022p-74\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal Type I error rate to the time to assess the efficacy of the anti-infective therapeutic \u0394\u003Cem\u003Et\u003C\/em\u003E. From the lower to upper end of each box plot, the five-parameter summary corresponds to [0%, 50%, 100%, 150%, 200%] of the baseline value \u0394\u003Cem\u003Et\u003C\/em\u003E = 1 week used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-9\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F11\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F11.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the incubation rate a of the infectious disease. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value a = 1 week used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the incubation rate \u0026lt;em\u0026gt;a\u0026lt;\/em\u0026gt; of the infectious disease. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026lt;em\u0026gt;a\u0026lt;\/em\u0026gt; = 1 week used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 11.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F11.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 11.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F11.medium.gif\u0022 width=\u0022440\u0022 height=\u0022423\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F11.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 11.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F11.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 11.\u003C\/span\u003E \u003Cp id=\u0022p-75\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal sample size (in each arm of non-adaptive Bayesian RCT) to the incubation rate \u003Cem\u003Ea\u003C\/em\u003E of the infectious disease. From the upper to lower end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u003Cem\u003Ea\u003C\/em\u003E = 1 week used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-10\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F12\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F12.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Sensitivity of optimal Type I error rate to the incubation rate a of the infectious disease. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value a = 1 week used in our analysis (Table 1).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Sensitivity of optimal Type I error rate to the incubation rate \u0026lt;em\u0026gt;a\u0026lt;\/em\u0026gt; of the infectious disease. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u0026lt;em\u0026gt;a\u0026lt;\/em\u0026gt; = 1 week used in our analysis (Table 1).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 12.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F12.medium.gif\u0022 width=\u0022440\u0022 height=\u0022419\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 12.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F12.medium.gif\u0022 width=\u0022440\u0022 height=\u0022419\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F12.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 12.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F12.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 12.\u003C\/span\u003E \u003Cp id=\u0022p-76\u0022 class=\u0022first-child\u0022\u003ESensitivity of optimal Type I error rate to the incubation rate \u003Cem\u003Ea\u003C\/em\u003E of the infectious disease. From the lower to upper end of each box plot, the five-parameter summary corresponds to [50%, 75%, 100%, 125%, 150%] of the baseline value \u003Cem\u003Ea\u003C\/em\u003E = 1 week used in our analysis (\u003Ca id=\u0022xref-table-wrap-1-11\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T7\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157509\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157509\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157509\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 6.\u003C\/span\u003E \u003Cp id=\u0022p-77\u0022 class=\u0022first-child\u0022\u003EOptimal sample size and Type I error rate \u003Cem\u003E\u03b1\u003C\/em\u003E for Bayesian non-adaptive RCT on anti-infective therapeutics with \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (basic reproduction number) close to 1. \u00b5 denotes the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size denotes the number of subjects enrolled in each arm of the RCT.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T8\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157504\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157504\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157504\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 7.\u003C\/span\u003E \u003Cp id=\u0022p-78\u0022 class=\u0022first-child\u0022\u003ESimulation results of Bayesian adaptive RCT on non-vaccine anti-infective therapeutics obtained from 10,000 Monte Carlo runs and assuming \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 10. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the basic reproduction number, \u00b5 the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size refers to the number of subjects enrolled in each arm of the RCT. SD denotes standard deviation, and IQR the interquartile range about the median. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E(t) denotes dynamic transmission model with half-life \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks and window length \u03c4 = 1 week.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022T9\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline table-callout-links\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u0022view-inline first\u0022\u003E\u003Ca href=\u0022\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/157524\/expansion?postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022view-popup\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/157524\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022download-ppt last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/157524\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 8.\u003C\/span\u003E \u003Cp id=\u0022p-79\u0022 class=\u0022first-child\u0022\u003ESimulation results of Bayesian adaptive RCT on vaccines obtained from 10,000 Monte Carlo runs and assuming \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 10. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E denotes the basic reproduction number, \u00b5 the disease morality, and \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E the proportion of initial infected subjects. Sample size refers to the number of subjects enrolled in each arm of the RCT. SD denotes standard deviation, and IQR the interquartile range about the median. \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (t) denotes dynamic transmission model with half-life \u003Cem\u003Et\u003C\/em\u003E\u003Csub\u003E2\u003C\/sub\u003E = 3 weeks and window length \u03c4 = 1 week.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022F13\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F13.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Optimal Type I error rate \u0026#x3B1; of non-adaptive Bayesian RCT monotonically increases with the basic reproduction number R0 (assuming I0 = 0. 1%, LD = 100 and disease mortality of COVID-19) if we define the loss of making a Type I error as the absolute risk of being susceptible S(t)NLS. This alternative definition is not very realistic. For an epidemic with R0 \u0026lt; 2, the loss of Type I error converges to a large positive value S(T)NLS as time approaches the end of the epidemic outbreak. However, at the end of the outbreak, there are no more infected patients and thus no susceptible subjects. Therefore, the loss of Type I error should approach zero as t \u0026#x2192; T. This is the case for the excess risk of susceptibility (S(t) - S(T))NLS but not for the absolute risk of susceptibility S(t)NLS.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1544872726\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;Optimal Type I error rate \u0026lt;em\u0026gt;\u0026#x3B1;\u0026lt;\/em\u0026gt; of non-adaptive Bayesian RCT monotonically increases with the basic reproduction number \u0026lt;em\u0026gt;R\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; (assuming \u0026lt;em\u0026gt;I\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; = 0. 1%, \u0026lt;em\u0026gt;L\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;D\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; = 100 and disease mortality of COVID-19) if we define the loss of making a Type I error as the absolute risk of being susceptible \u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;(\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt;)\u0026lt;em\u0026gt;NL\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;. This alternative definition is not very realistic. For an epidemic with \u0026lt;em\u0026gt;R\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;0\u0026lt;\/sub\u0026gt; \u0026lt; 2, the loss of Type I error converges to a large positive value \u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;(\u0026lt;em\u0026gt;T\u0026lt;\/em\u0026gt;)\u0026lt;em\u0026gt;NL\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; as time approaches the end of the epidemic outbreak. However, at the end of the outbreak, there are no more infected patients and thus no susceptible subjects. Therefore, the loss of Type I error should approach zero as \u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt; \u0026#x2192; \u0026lt;em\u0026gt;T\u0026lt;\/em\u0026gt;. This is the case for the excess risk of susceptibility (\u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;(\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt;) - \u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;(\u0026lt;em\u0026gt;T\u0026lt;\/em\u0026gt;))\u0026lt;em\u0026gt;NL\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt; but not for the absolute risk of susceptibility \u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;(\u0026lt;em\u0026gt;t\u0026lt;\/em\u0026gt;)\u0026lt;em\u0026gt;NL\u0026lt;\/em\u0026gt;\u0026lt;sub\u0026gt;\u0026lt;em\u0026gt;S\u0026lt;\/em\u0026gt;\u0026lt;\/sub\u0026gt;.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 13.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F13.medium.gif\u0022 width=\u0022440\u0022 height=\u0022366\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 13.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F13.medium.gif\u0022 width=\u0022440\u0022 height=\u0022366\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F13.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 13.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2020\/04\/14\/2020.04.09.20059634\/F13.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 13.\u003C\/span\u003E \u003Cp id=\u0022p-80\u0022 class=\u0022first-child\u0022\u003EOptimal Type I error rate \u003Cem\u003E\u03b1\u003C\/em\u003E of non-adaptive Bayesian RCT monotonically increases with the basic reproduction number \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E (assuming \u003Cem\u003EI\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E = 0. 1%, \u003Cem\u003EL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ED\u003C\/em\u003E\u003C\/sub\u003E = 100 and disease mortality of COVID-19) if we define the loss of making a Type I error as the absolute risk of being susceptible \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E)\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ES\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-81\u0022\u003EThis alternative definition is not very realistic. For an epidemic with \u003Cem\u003ER\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E \u0026lt; 2, the loss of Type I error converges to a large positive value \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E)\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ES\u003C\/em\u003E\u003C\/sub\u003E as time approaches the end of the epidemic outbreak. However, at the end of the outbreak, there are no more infected patients and thus no susceptible subjects. Therefore, the loss of Type I error should approach zero as \u003Cem\u003Et\u003C\/em\u003E \u2192 \u003Cem\u003ET\u003C\/em\u003E. This is the case for the excess risk of susceptibility (\u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E) - \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003ET\u003C\/em\u003E))\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ES\u003C\/em\u003E\u003C\/sub\u003E but not for the absolute risk of susceptibility \u003Cem\u003ES\u003C\/em\u003E(\u003Cem\u003Et\u003C\/em\u003E)\u003Cem\u003ENL\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003ES\u003C\/em\u003E\u003C\/sub\u003E.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section fn-group\u0022 id=\u0022fn-group-1\u0022\u003E\u003Ch2\u003EFootnotes\u003C\/h2\u003E\u003Cul\u003E\u003Cli class=\u0022fn-other\u0022 id=\u0022fn-1\u0022\u003E\u003Cp id=\u0022p-1\u0022\u003E\u003Cspan class=\u0022fn-label\u0022\u003E*\u003C\/span\u003E We thank Murray Sheldon, Chi Heem Wong, the editor, associate editor, and reviewer for many helpful comments and suggestions, and Jayna Cummings for editorial assistance. Research support from the MIT Laboratory for Financial Engineering is gratefully acknowledged. The views and opinions expressed in this article are those of the authors only, and do not represent the views, policies, and opinions any institution or agency, any of their affiliates or employees, or any of the individuals acknowledged above.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.1\u0022 data-doi=\u002210.1158\/1078-0432.CCR-17-0764\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAlexander\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. M.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EAdaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EClinical Cancer Research\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E24\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E), \u003Cspan class=\u0022cit-fpage\u0022\u003E737\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E43\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DClinical%2BCancer%2BResearch%26rft_id%253Dinfo%253Adoi%252F10.1158%252F1078-0432.CCR-17-0764%26rft_id%253Dinfo%253Apmid%252F28814435%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTA6ImNsaW5jYW5yZXMiO3M6NToicmVzaWQiO3M6ODoiMjQvNC83MzciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMC8wNC8xNC8yMDIwLjA0LjA5LjIwMDU5NjM0LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.2\u0022 data-doi=\u002210.1016\/j.molonc.2015.02.011\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarry\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EThe Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMolecular Oncology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E5\u003C\/span\u003E), \u003Cspan class=\u0022cit-fpage\u0022\u003E951\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E959\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMolecular%2BOncology%26rft.volume%253D9%26rft.spage%253D951%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.molonc.2015.02.011%26rft_id%253Dinfo%253Apmid%252F25888066%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.molonc.2015.02.011\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25888066\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhuri\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. E.\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EBayesian Adaptive Patient-Centered Clinical Trials\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003Epreprint\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhuri\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. E.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESheldon\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIrony\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EPatient-Centered Clinical Trials\u003C\/span\u003E,\u201d \u003Cspan class=\u0022cit-source\u0022\u003EDrug Discovery Today\u003C\/span\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E23\u003C\/span\u003E,\u003Cspan class=\u0022cit-fpage\u0022\u003E395\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E401\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/doi.org\/10.1016\/j.drudis.2017.09.016\u0022\u003Ehttps:\/\/doi.org\/10.1016\/j.drudis.2017.09.016\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DDrug%2BDiscovery%2BToday%26rft.volume%253D23%26rft.spage%253D395%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhuri\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. E.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHauber\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMange\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhou\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESaha\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECaldwell\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBenz\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH. L.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERuiz\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChristopher\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBardot\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESheehan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDonnelly\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMcLaughlin\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGwinn\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESheldon\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E and \u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E). \u003Cspan class=\u0022cit-article-title\u0022\u003E\u201cUse of Bayesian Decision Analysis to Maximize Value in Patient-Centered Randomized Clinical Trials in Parkinson\u003C\/span\u003E\u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003E\u2019s Disease,\u201d preprint\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBarker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESigman\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKelloff\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHylton\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBerry\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEsserman\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2009\u003C\/span\u003E). \u003Cspan class=\u0022cit-article-title\u0022\u003E\u201cI-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy,\u201d Clinical Pharmacology \u0026amp;\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETherapeutics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E86\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E97\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E100\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTherapeutics%26rft.volume%253D86%26rft.spage%253D97%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EIsakov\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMontazerhodjat\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E) \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EIs the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Econometrics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E211\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E117\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E136\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2BEconometrics%26rft.volume%253D211%26rft.spage%253D117%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKucharski\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EEarly dynamics of transmission and control of COVID-19: a mathematical modelling study\u003C\/span\u003E,\u201d \u003Cspan class=\u0022cit-source\u0022\u003EThe Lancet Infectious Diseases. Published online March 11, 2020\u003C\/span\u003E. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EApril 6, 2020. doi\u003C\/span\u003E: \u003Ca href=\u0022https:\/\/doi.org\/10.1016\/S1473-3099(20)30144-4\u0022\u003Ehttps:\/\/doi.org\/10.1016\/S1473-3099(20)30144-4\u003C\/a\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMontazerhodjat\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EV.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChaudhuri\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. E.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESargent\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED. J.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EUse of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology\u003C\/span\u003E\u201d, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA Oncology\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E3\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.10\u0022 data-doi=\u002210.1056\/NEJMoa2001316\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EQ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EEarly Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENew England Journal of Medicine\u003C\/abbr\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi: \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1056\/NEJMoa2001316\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2001316%26rft_id%253Dinfo%253Apmid%252F31995857%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2001316\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31995857\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.11\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EDiscussion: New directions for the FDA in the 21st century\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiostatistics\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E18\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E404\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E407\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiostatistics%26rft.volume%253D18%26rft.spage%253D404%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.12\u0022 data-doi=\u002210.1186\/s12916-016-0553-2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOnakpoya\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EI.J.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHeneghan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.J.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAronson\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.K.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EPost-Marketing Withdrawal of 462 Medicinal Products Because of Adverse Drug Reactions: A Systematic Review of the World Literature\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Medicine\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E).\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1186\/s12916-016-0553-2\u003C\/span\u003E [published correction appears in BMC Medicine, 2019 \u003Cspan class=\u0022cit-month\u0022\u003EMar\u003C\/span\u003E 2;17(1):\u003Cspan class=\u0022cit-fpage\u0022\u003E56\u003C\/span\u003E].\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBMC%2BMedicine%26rft.volume%253D14%26rft.spage%253D56%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs12916-016-0553-2%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1186\/s12916-016-0553-2\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.13\u0022 data-doi=\u002210.1001\/jama.2020.4683\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOnder\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERezza\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrusaferro\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003ECase-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy\u003C\/span\u003E,\u201d \u003Cspan class=\u0022cit-source\u0022\u003EJAMA. Published online March 23, 2020\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003Eon March 28, 2020\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1001\/jama.2020.4683\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA.%2BPublished%2Bonline%2BMarch%2B23%252C%2B2020%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2020.4683%26rft_id%253Dinfo%253Apmid%252F32203977%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.2020.4683\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32203977\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.14\u0022 data-doi=\u002210.1371\/journal.pone.0057755\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPronker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. S.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeenen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET. C.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECommandeur\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EClaassen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. H.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EOsterhaus\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. D.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E) \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003ERisk in vaccine research and development quantified\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003Ee57755\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D8%26rft.spage%253De57755%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0057755%26rft_id%253Dinfo%253Apmid%252F23526951%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1371\/journal.pone.0057755\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23526951\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.15\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Census Bureau\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E). Available online at \u003Ca href=\u0022https:\/\/data.census.gov\/\u0022\u003Ehttps:\/\/data.census.gov\/\u003C\/a\u003E. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 28, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-web no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.16\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Food \u0026amp; Drug Administration\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003E\u201cStructured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA V Implementation Plan\u2014February 2013, Fiscal Years 2013-2017\u201d. Available online at\u003C\/span\u003E \u003Ca href=\u0022http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM329758.pdf\u0022\u003Ehttp:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM329758.pdf\u003C\/a\u003E. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 20, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.17\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EU.S. Food \u0026amp; Drug Administration\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003E\u201cVaccine Product Approval Process\u201d\u003C\/span\u003E. Available online: \u003Ca href=\u0022https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/vaccine-product-approval-process\u0022\u003Ehttps:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/vaccine-product-approval-process\u003C\/a\u003E. Published online January 30, 2018. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 8, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.18\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWalker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. G. T.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWhittaker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWatson\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E) \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EReport 12: The Global Impact of COVID-19 and Strategies for Mitigation and Suppression\u003C\/span\u003E,\u201d \u003Cspan class=\u0022cit-source\u0022\u003EWHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London\u003C\/span\u003E. Available online: \u003Ca href=\u0022https:\/\/www.imperial.ac.uk\/mrc-global-infectious-disease-analysis\/news--wuhan-coronavirus\/\u0022\u003Ehttps:\/\/www.imperial.ac.uk\/mrc-global-infectious-disease-analysis\/news--wuhan-coronavirus\/\u003C\/a\u003E. Published online March 26, 2020. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 28, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.19\u0022 data-doi=\u002210.1093\/biostatistics\/kxx069\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. H.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiah\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. W.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EEstimation of clinical trial success rates and related parameters\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiostatistics\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E20\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E), \u003Cspan class=\u0022cit-fpage\u0022\u003E273\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E286\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiostatistics%26rft.volume%253D20%26rft.spage%253D273%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fbiostatistics%252Fkxx069%26rft_id%253Dinfo%253Apmid%252F29394327%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/biostatistics\/kxx069\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=29394327\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWong\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. H.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESiah\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK. W.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELo\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. W.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EEstimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003Epreprint, MIT Laboratory for Financial Engineering\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-month\u0022\u003EApril\u003C\/span\u003E 8.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.21\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003E\u201cCoronavirus disease 2019 (COVID-19) Situation report\u201359\u201d\u003C\/span\u003E. Available online: \u003Ca href=\u0022https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdef9_2\u0022\u003Ehttps:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdef9_2\u003C\/a\u003E. Published online March 19, 2020. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 19, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.22\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EConsensus document on the epidemiology of severe acute respiratory syndrome (SARS)\u003C\/span\u003E\u201d. Available online: \u003Ca href=\u0022https:\/\/www.who.int\/csr\/sars\/en\/WHOconsensus.pdf\u0022\u003Ehttps:\/\/www.who.int\/csr\/sars\/en\/WHOconsensus.pdf\u003C\/a\u003E. Published online November, 2003. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 8, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2020.04.09.20059634v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EWorld Health Organization\u003C\/span\u003E. (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E). \u003Cspan class=\u0022cit-source\u0022\u003E\u201cMERS situation update, December 2019,\u201d\u003C\/span\u003E Available online: \u003Ca href=\u0022http:\/\/www.emro.who.int\/pandemic-epidemic-diseases\/mers-cov\/mers-situation-update-december-2019.html\u0022\u003Ehttp:\/\/www.emro.who.int\/pandemic-epidemic-diseases\/mers-cov\/mers-situation-update-december-2019.html\u003C\/a\u003E. Published online December, 2019. Accessed on \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EMarch 28, 2020\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2020.04.09.20059634v1.24\u0022 data-doi=\u002210.1016\/S0140-6736(20)30260-9\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWu\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. T.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeung\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E\u003C\/span\u003E, and \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeung\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. M.\u003C\/span\u003E\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003ENowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E395\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E689\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E697\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%26rft.volume%253D395%26rft.spage%253D689%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252820%252930260-9%26rft_id%253Dinfo%253Apmid%252F32014114%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0140-6736(20)30260-9\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32014114\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.25\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYang\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EZ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EModified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJournal of Thoracic Disease\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2020.04.09.20059634v1.26\u0022 data-doi=\u002210.1016\/j.ijid.2020.01.050\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZhao\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E). \u201c\u003Cspan class=\u0022cit-article-title\u0022\u003EPreliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak\u003C\/span\u003E,\u201d \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInternational Journal of Infectious Diseases\u003C\/abbr\u003E, \u003Cspan class=\u0022cit-vol\u0022\u003E92\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E214\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E217\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInternational%2BJournal%2Bof%2BInfectious%2BDiseases%26rft.volume%253D92%26rft.spage%253D214%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ijid.2020.01.050%26rft_id%253Dinfo%253Apmid%252F32007643%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.ijid.2020.01.050\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=32007643\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F04%2F14%2F2020.04.09.20059634.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_zP7WWIfzbyzvaM63L39cNV2juU_1XVH7wduFK9gcMNI.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}